Magnitude and Duration of Serum Neutralizing Antibody Titers Induced by a Third mRNA COVID-19 Vaccination against Omicron BA.1 in Older Individuals-Reference-Cited by-同舟云学术

Magnitude and Duration of Serum Neutralizing Antibody Titers Induced by a Third mRNA COVID-19 Vaccination against Omicron BA.1 in Older Individuals

Published:2024 Issue:1 Volume:56 Page:25
ISSN:2093-2340
Container-title:Infection & Chemotherapy
language:en
Short-container-title:Infect Chemother

Author:

Park Jun-Sun¹^ORCID,Jeon Jaehyun²^ORCID,Um Jihye¹^ORCID,Choi Youn Young³^ORCID,Kim Min-Kyung²^ORCID,Lee Kyung-Shin¹^ORCID,Sung Ho Kyung¹^ORCID,Jang Hee-Chang⁴^ORCID,Chin BumSik²^ORCID,Kim Choon Kwan⁵^ORCID,Oh Myung-don⁶^ORCID,Lee Chang-Seop⁷⁸^ORCID

Affiliation:

1. Research Institute for Public Healthcare, National Medical Center, Seoul, Korea.

2. Department of Infectious Diseases, National Medical Center, Seoul, Korea.

3. Department of Pediatrics, National Medical Center, Seoul, Korea.

4. National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Korea.

5. Division of Infectious Diseases, VHS Medical Center, Seoul, Korea.

6. Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.

7. Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Korea.

8. Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea.

Funder

Korea Disease Control and Prevention Agency

Publisher

XMLink

Link

https://icjournal.org/pdf/10.3947/ic.2023.0057

Reference39 articles.

1. World Health Organization (WHO). Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern. Accessed 29 October 2022. Available at: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern

2. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa

3. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

4. SARS-CoV-2, COVID-19 and the aging immune system